China National Accord Medicines Corporation Ltd. (SHE:000028)
China
· Delayed Price · Currency is CNY 24.80
+0.11 (0.45%)
Apr 29, 2026, 3:04 PM CST
SHE:000028 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 72,308 | 72,778 | 73,675 | 74,844 | 72,701 | 67,648 | Upgrade
|
| Other Revenue | 637.52 | 637.52 | 703 | 633.35 | 742.57 | 710.01 | Upgrade
|
| Revenue | 72,946 | 73,416 | 74,378 | 75,477 | 73,443 | 68,358 | Upgrade
|
| Revenue Growth (YoY) | -0.86% | -1.29% | -1.46% | 2.77% | 7.44% | 14.60% | Upgrade
|
| Cost of Revenue | 65,618 | 65,618 | 66,180 | 66,471 | 64,561 | 60,372 | Upgrade
|
| Gross Profit | 7,327 | 7,797 | 8,198 | 9,006 | 8,883 | 7,986 | Upgrade
|
| Selling, General & Admin | 5,811 | 5,811 | 6,407 | 6,404 | 6,374 | 5,772 | Upgrade
|
| Research & Development | 19.99 | 19.99 | 24.55 | 26.82 | 9.07 | - | Upgrade
|
| Other Operating Expenses | -245.63 | 161.93 | 116.3 | 93.73 | 180.1 | 139.09 | Upgrade
|
| Operating Expenses | 5,670 | 6,077 | 6,642 | 6,596 | 6,585 | 5,955 | Upgrade
|
| Operating Income | 1,658 | 1,720 | 1,556 | 2,411 | 2,298 | 2,031 | Upgrade
|
| Interest Expense | -194.5 | -194.5 | -258.3 | -248.38 | -261.91 | -288.04 | Upgrade
|
| Interest & Investment Income | 264.56 | 264.56 | 300.32 | 314.58 | 212.07 | 366.68 | Upgrade
|
| Currency Exchange Gain (Loss) | 1.37 | 1.37 | -1.85 | 2.95 | -0.44 | 0.41 | Upgrade
|
| Other Non Operating Income (Expenses) | -42.53 | -43.62 | -28.62 | -27.9 | -1.89 | -4.87 | Upgrade
|
| EBT Excluding Unusual Items | 1,687 | 1,748 | 1,568 | 2,452 | 2,245 | 2,105 | Upgrade
|
| Impairment of Goodwill | -253.92 | -253.92 | -887.85 | - | -38.98 | -162.69 | Upgrade
|
| Gain (Loss) on Sale of Investments | 3.13 | 3.13 | -22.81 | -15.16 | 28.87 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 7.96 | 7.96 | 11.87 | 45.31 | 8.31 | 4.25 | Upgrade
|
| Asset Writedown | -31.84 | -31.84 | -84 | -0.64 | -18.87 | -75.55 | Upgrade
|
| Legal Settlements | -0.31 | -0.31 | -0.51 | -3.25 | -0.05 | -0.55 | Upgrade
|
| Other Unusual Items | 36 | 36 | -9.16 | -5.12 | 86.36 | 104.09 | Upgrade
|
| Pretax Income | 1,448 | 1,509 | 575.47 | 2,473 | 2,311 | 1,975 | Upgrade
|
| Income Tax Expense | 359.74 | 380.67 | 338.47 | 514.74 | 539.33 | 447.21 | Upgrade
|
| Earnings From Continuing Operations | 1,088 | 1,128 | 237 | 1,958 | 1,772 | 1,528 | Upgrade
|
| Minority Interest in Earnings | 7.58 | 7.58 | 405.49 | -359.23 | -285.03 | -191.21 | Upgrade
|
| Net Income | 1,095 | 1,136 | 642.49 | 1,599 | 1,487 | 1,336 | Upgrade
|
| Net Income to Common | 1,095 | 1,136 | 642.49 | 1,599 | 1,487 | 1,336 | Upgrade
|
| Net Income Growth | 88.30% | 76.80% | -59.82% | 7.57% | 11.24% | -4.67% | Upgrade
|
| Shares Outstanding (Basic) | 556 | 557 | 559 | 557 | 557 | 557 | Upgrade
|
| Shares Outstanding (Diluted) | 556 | 557 | 559 | 557 | 557 | 557 | Upgrade
|
| Shares Change (YoY) | -0.16% | -0.38% | 0.26% | 0.12% | - | - | Upgrade
|
| EPS (Basic) | 1.97 | 2.04 | 1.15 | 2.87 | 2.67 | 2.40 | Upgrade
|
| EPS (Diluted) | 1.97 | 2.04 | 1.15 | 2.87 | 2.67 | 2.40 | Upgrade
|
| EPS Growth | 89.31% | 77.39% | -59.93% | 7.49% | 11.25% | -4.59% | Upgrade
|
| Free Cash Flow | - | 1,421 | 2,989 | 2,615 | 2,238 | 1,285 | Upgrade
|
| Free Cash Flow Per Share | - | 2.55 | 5.35 | 4.69 | 4.02 | 2.31 | Upgrade
|
| Dividend Per Share | 0.616 | 0.616 | 0.366 | 0.680 | 0.615 | 0.462 | Upgrade
|
| Dividend Growth | 68.31% | 68.31% | -46.18% | 10.50% | 33.35% | -25.01% | Upgrade
|
| Gross Margin | 10.04% | 10.62% | 11.02% | 11.93% | 12.09% | 11.68% | Upgrade
|
| Operating Margin | 2.27% | 2.34% | 2.09% | 3.19% | 3.13% | 2.97% | Upgrade
|
| Profit Margin | 1.50% | 1.55% | 0.86% | 2.12% | 2.02% | 1.96% | Upgrade
|
| Free Cash Flow Margin | - | 1.94% | 4.02% | 3.46% | 3.05% | 1.88% | Upgrade
|
| EBITDA | 1,536 | 1,932 | 3,102 | 3,836 | 2,542 | 2,239 | Upgrade
|
| EBITDA Margin | 2.11% | 2.63% | 4.17% | 5.08% | 3.46% | 3.28% | Upgrade
|
| D&A For EBITDA | -121.32 | 212.01 | 1,545 | 1,426 | 244.32 | 207.45 | Upgrade
|
| EBIT | 1,658 | 1,720 | 1,556 | 2,411 | 2,298 | 2,031 | Upgrade
|
| EBIT Margin | 2.27% | 2.34% | 2.09% | 3.19% | 3.13% | 2.97% | Upgrade
|
| Effective Tax Rate | 24.85% | 25.23% | 58.82% | 20.81% | 23.34% | 22.64% | Upgrade
|
| Revenue as Reported | 73,416 | 73,416 | 74,378 | 75,477 | - | - | Upgrade
|
| Advertising Expenses | - | - | - | - | 46.67 | 44.12 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.